Visterra 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Equillium 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Suciraslimab, an antibody targeting CD22.

Escient Pharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

NImmune Biopharma 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Iparomlimab, an antibody targeting PD-1.

Parvus Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Mozart Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Santa Ana Bio 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Picankibart, an antibody targeting IL-23p19.

Instil Bio 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sipavibart, an antibody targeting SARS-CoV-2 Spike RBD.